Stratec (SBS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Q1 2026 saw a significant rise in free cash flow to €18.6 million from €-8.3 million in Q1 2025, despite declines in sales and profitability, which remained within planned expectations.
Systems business maintained strong double-digit growth, while Service Parts and Consumables, and Development and Services segments saw declines due to customer logistics optimization and challenging comparables.
Efficiency and cost management measures were advanced, and the development pipeline remains robust with projects moving toward serial production and ongoing negotiations for new collaborations.
Revenue and profitability trends mirror broader market softness, with a significant back-end loaded year expected and full-year 2026 guidance reaffirmed.
Financial highlights
Q1 2026 revenue was €53.4 million, down 11.5% year-over-year (8.8% at constant currency).
Adjusted EBIT was €0.7 million, margin 1.3%, reflecting an 87.1% year-over-year decline.
Adjusted EBITDA dropped 49.6% to €4.7 million; margin fell to 8.8%.
Adjusted net income was €-1.1 million, with adjusted EPS at €-0.09.
Free cash flow improved to €18.6 million, driven by reduced trade receivables and working capital management.
Outlook and guidance
2026 guidance confirmed: constant-currency sales growth expected in the mid- to high single-digit percentage range.
Adjusted EBIT margin for 2026 projected to remain around the 2025 level (10.0%), with scale benefits offset by rising input costs.
Year expected to be heavily weighted to H2, with Q4 as the strongest quarter.
Investments in tangible and intangible assets projected at 6.5%–8.5% of revenue.
Long-term targets: sales CAGR of 6–8% (2025–2028), 10–12% (2028–2030); EBIT margin ≥13% by 2028, ≥15% by 2030.
Latest events from Stratec
- Stable 2025 sales and margins, strong Q4 systems growth, and positive long-term outlook.SBS
Q4 202528 Apr 2026 - Margins and cash flow improved despite lower sales; 2024 guidance remains unchanged.SBS
Q2 20241 Feb 2026 - Sales down 6.1% Y/Y; margins stable; Q4 rebound expected from new orders and deliveries.SBS
Q3 202418 Jan 2026 - Stable margins and recurring revenues support growth as innovation and M&A drive recovery.SBS
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Margin and cash flow gains in 2024; 2025 to see modest growth and margin normalization.SBS
Q4 202426 Nov 2025 - Sales up 5.2% YoY; margins down on FX; H2 to see sales and margin improvement.SBS
Q2 202523 Nov 2025 - Consumables and service parts now lead revenue, with growth set to return as replacement cycles accelerate.SBS
Health Care Conference14 Nov 2025 - Sales up 2.5% at constant currency, but margins and net income declined amid supply chain challenges.SBS
Q3 20257 Nov 2025 - Profitability and cash flow improved despite lower sales, with a focus on high-growth diagnostics markets.SBS
Investor Presentation27 Jun 2025